NCT05866809View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

June 23, 2023

Study Completion Date

July 24, 2023

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

HK-660S

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (4)

02080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Seoul

05505

ASAN Medical Center, Seoul

06351

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

CuromeBiosciences
All Listed Sponsors
lead

CuromeBiosciences

INDUSTRY

NCT05866809 - Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis | Biotech Hunter | Biotech Hunter